Results 171 to 180 of about 10,477 (203)
Some of the next articles are maybe not open access.
Expert Opinion on Biological Therapy, 2008
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
+6 more sources
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
+6 more sources
Expert Review of Clinical Immunology, 2005
Etanercept is a member of a new generation of therapeutic agents referred to as biologics or targeted therapies, which have caused some enthusiasm in the field of autoimmune disorders in recent years. Most of these agents are inhibitors of tumor necrosis factor, a key cytokine in the chronic inflammatory process.
Mathias, Grunke, Joachim Robert, Kalden
openaire +2 more sources
Etanercept is a member of a new generation of therapeutic agents referred to as biologics or targeted therapies, which have caused some enthusiasm in the field of autoimmune disorders in recent years. Most of these agents are inhibitors of tumor necrosis factor, a key cytokine in the chronic inflammatory process.
Mathias, Grunke, Joachim Robert, Kalden
openaire +2 more sources
Annales de Dermatologie et de Vénéréologie, 2005
Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p.
openaire +3 more sources
Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p.
openaire +3 more sources
Journal of the American Academy of Dermatology, 2003
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Ben, Goffe, Jennifer Clay, Cather
openaire +2 more sources
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Ben, Goffe, Jennifer Clay, Cather
openaire +2 more sources
BioDrugs, 2004
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire +2 more sources
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire +2 more sources
Etanercept combined with methotrexate for high-need psoriasis [PDF]
British Journal of Dermatology, 2008 Contains fulltext : 70381.pdf (Publisher’s version ) (Open Access)BACKGROUND: For some high-need psoriatic patients, the efficacy of etanercept monotherapy is insufficient. In these cases it might be indicated to combine etanercept with
exaly +2 more sources
Expert Opinion on Pharmacotherapy, 2004
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Several lines of evidence have demonstrated the correlation between elevated levels of TNF and psoriasis, suggesting that interfering with the inflammatory effects of TNF may help resolve psoriatic lesions. The biological agent, etanercept, is a fully
openaire +2 more sources
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Several lines of evidence have demonstrated the correlation between elevated levels of TNF and psoriasis, suggesting that interfering with the inflammatory effects of TNF may help resolve psoriatic lesions. The biological agent, etanercept, is a fully
openaire +2 more sources